e18824 Background: In the past decade, oncology site of care (SOC) for drug infusions has shifted from physicians’ offices to hospital outpatient settings. This shift has raised questions regarding the potential impact of SOC on the value of cancer care. The purpose of this study is to explore current potential cost savings among select infused cancer therapies in stable patients transitioning from an outpatient setting to an office setting. Methods: We identified patients with cancer receiving a check-point inhibitor using medical claims data from June 30, 2018, to June 30, 2021, at a large national commercial insurer. We defined a non-stable patient as a patient who had yet to receive treatment for 180 days and/or may not be clinically stable to transition. A stable patient was defined as having received 180 days of treatment and further divided into either the “stable outpatient,” “stable office,” or “ineligible” group. Stable outpatient was defined as having the first, 6 month and last SOC in an outpatient setting. Stable office was defined as having the first, 6 month and last SOC in an office setting. Ineligible patients included those patients moving between the outpatient and office setting during the study period. We compared the stable outpatient and stable office groups using a t-test and simulated the potential savings of moving stable patients from the outpatient setting to the office, adjusting for drug, insurance type and state. Results: This study included 2,727 patients, of which 511 (18.7%) were stable. Of this stable population, the majority were outpatient 311 (60.9%) and 178 (34.8%) were office; 22 (4.3%) were ineligible. We examined the cost differences of select infusion drugs between the stable outpatient and stable office settings and observed significant cost differences across all drugs (p < 0.01). Based on our observations, 83 (27%) stable outpatient patients are expected to transition to stable office patients during the study period. After adjusting for drug, insurance type and state, transitioning these patients would be $71,169 ($55,259 to $81,709) less costly per patient per year. Conclusions: Our results suggest significant cost savings by transitioning stable outpatient patients to the office setting. Encouraging stable patients to transition from the outpatient setting to the office setting may improve the value of cancer care by reducing the unit cost of therapy, which is key to practices as value-based contracting expands.